KNSA Kiniksa Pharmaceuticals, Ltd.
USHealthcareAs of 2026-07-10 16:00
Why KNSA matters now
Kiniksa Pharmaceuticals, Ltd. (KNSA) is a US stock in Healthcare. The latest InvestLog snapshot shows $63.44 with -2.97% on the session and $4.77B in market capitalization; recent performance reads 1-month +3.32% and YTD +33.60%.
The latest financial table shown here is Q1 2026, with revenue of $214.3M, net income of $22.6M, and EPS of $0.27. Investors can compare that operating picture with valuation signals such as P/E 59.21 and FCF yield 4.0%.
The latest indexable market news headline is "Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $62.00; recent insider activity includes Patel Sanj K filing C-Conversion. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
59.21
PEG
0.25
P/B
6.96
P/S
5.49
EV/EBITDA
36.80
DCF Value
$-687.21
FCF Yield
4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.6%
Operating Margin
12.4%
Net Margin
9.7%
ROE
13.3%
ROA
8.9%
ROIC
9.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $214.3M | $22.6M | $0.27 |
| Q4 2025 | $202.1M | $14.2M | $0.18 |
| FY 2025 | $677.6M | $59.0M | $0.75 |
| Q3 2025 | $180.9M | $18.4M | $0.23 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$64.00
Target (Median)
$62.00
Target Range
$59.00 - $71.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.12
Kiniksa Pharmaceuticals, Ltd. is a global biopharmaceutical firm dedicated to discovering, acquiring, advancing, and commercializing medical therapies for individuals suffering from severe illnesses where current treatment options are insufficient. Its pipeline of potential treatments includes ARCALYST, an interleukin-1alpha and interleukin-1beta inhibitor, aimed at addressing recurrent pericarditis, an inflammatory heart condition. Also in development is Mavrilimumab, a monoclonal antibody inhibitor that has successfully concluded Phase II clinical trials for managing giant cell arteritis. Additionally, Vixarelimab, another monoclonal antibody, is currently undergoing Phase 2a clinical trials as a potential therapy for prurigo nodularis, a persistent inflammatory skin disorder. The company's pipeline further includes KPL-404, a monoclonal antibody engineered to inhibit the CD40-CD154 interaction, which plays a crucial role in T-cell co-stimulation, B-cell development, immunoglobulin class switching, and the body's type 1 immune response. Established in 2015, Kiniksa Pharmaceuticals, Ltd. operates from its headquarters in Hamilton, Bermuda.